The company’s drug aficamten hit both its endpoints in a study in a condition known as nHCM
Adobe
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
It took Cytokinetics 27 years to win its first regulatory approval. The second one could happen much faster than that.
The biotech on Friday unveiled the full pivotal study data of its drug aficamten in an inherited heart condition called non-obstructive hypertrophic cardiomyopathy, showing that the medicine improved how patients felt and their exercise capacity.
